Clinical Research Directory
Browse clinical research sites, groups, and studies.
Fexofenadine as Adjuvant Therapy in Parkinson Disease
Sponsor: Tanta University
Summary
Parkinson's disease (PD) is a chronic, progressive neurological disorder characterized by both motor and non-motor symptoms. PD is the second most common neurodegenerative disorder after Alzheimer's disease and the most common movement disorder. PD has age-related pathology; it is present in 1-2% of the population over 60 years of age. The disease is characterized by a triad of disordered voluntary motor activity in the form of bradykinesia (slowness of movement) or even akinesia (absence of movement),rigidity and postural instability, and a resting tremor of the hands and less commonly the feet.
Official title: Clinical Study to Evaluate the Possible Efficacy and Safety of Fexofenadine in Patients With Parkinson's Disease Treated With Conventional Treatment
Key Details
Gender
All
Age Range
50 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2024-12-10
Completion Date
2026-12-20
Last Updated
2026-01-21
Healthy Volunteers
No
Conditions
Interventions
Levodopa/carbidopa
A dopamine precursor, was first developed for the treatment of PD in the 1960s and continues to be the most-effective therapeutic agent for PD
Fexofenadine
Fexofenadine is a second-generation antihistamine that does not penetrate the CNS and has the least CNS side effects among the second-generation antihistamines
Locations (1)
Tanta University
Tanta, Egypt